What's in French Innovative Leukemia Organisation's pipeline?

French Innovative Leukemia Organisation has 17 drugs in our index: 1 marketed, 0 filed, 3 in Phase 3, 12 in Phase 2, 1 in Phase 1.

Which companies overlap with French Innovative Leukemia Organisation's portfolio?

Top competitors by shared drug class: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Canadian Cancer Trials Group, Centre Georges Francois Leclerc, Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/french-innovative-leukemia-organisation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

French Innovative Leukemia Organisation — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

French Innovative Leukemia Organisation pipeline: 1 marketed, 0 filed, 3 Phase 3, 12 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 12 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Xospata	Xospata	marketed		ADP/ATP translocase 2, ADP/ATP translocase 3, Bone morphogenetic protein receptor type-1B	Oncology
Experimental (fludarabine)	Experimental (fludarabine)	phase 3	Purine analog antimetabolite	Ribonucleotide reductase, DNA polymerase	Oncology
MINI CHEP	MINI CHEP	phase 3			Oncology
Lomustine, intermediate dose cytarabine	Lomustine, intermediate dose cytarabine	phase 3	Alkylating agent + nucleoside antimetabolite combination		Oncology

Therapeutic area mix

Oncology · 8
Other · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
Canadian Cancer Trials Group · 1 shared drug class
Centre Georges Francois Leclerc · 1 shared drug class
Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
Chinese PLA General Hospital · 1 shared drug class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
AIO-Studien-gGmbH · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for French Innovative Leukemia Organisation:

Cite this brief

Drug Landscape (2026). French Innovative Leukemia Organisation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/french-innovative-leukemia-organisation. Accessed 2026-05-16.